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Introduction: Impulse control disorders (ICDs) are a common complication of
Parkinson’s disease (PD) receiving dopamine agonist (DAA) Impulsivity is considered
an underlying mechanism but evidence of this relationship is scarce. To explore the
relationship between impulsivity and the presence and severity of ICD in PD.
Methods: Prospective cross-sectional study of consecutive PD outpatients. Patients
with dementia or previously known ICDs were excluded. Two measures of impulsivity
were assessed: Barratt Impulsiveness Scale (BIS-11) for impulsiveness trait (main
exposure) and commission errors in the Continuous Performance Test (CE) for motor
inhibition. Main outcomes were diagnosis of ICD based on a comprehensive clinical
interview and severity of ICD based on the Questionnaire for Impulsive-Compulsive
Disorders.
Results: Of 100 patients (mean [SD] age, 67.2 [8.8], 54 male), 31 had ICD. Patients
with ICDs were 5.3 years younger (p = 0.01), used more frequently dopamine agonist
(p = 0.02), alcohol (p = 0.009) and tobacco (p = 0.02). They were not more impulsive
on BIS-11 (56 vs. 58, p = 0.23, adjusted p = 0.46) and CE (p = 0.96). No relationship
was found between dopaminergic medications and impulsivity or ICD severity. Among
patients with ICD, impulsivity was correlated with ICD severity (BIS-11 r = 0.33,
p= 0.001, adjusted p= 0.002, CE r = 0.53, p= 0.006). Multivariate regression analysis
confirmed the independent predictive role of both measures.
Conclusions: Impulsivity is not associated with increased prevalence of ICD in PD but
it is strongly linked to ICD severity. When considering dopamine replacement therapy,
assessment of impulsivity may be a useful approach to detect those patients at risk of
severe forms of ICD.
Keywords: impulsivity, impulse control disorders, behavioral addictions, Parkinson’s disease, severity
Marín-Lahoz et al. Impulsivity and Severity in PD ICD
INTRODUCTION
Impulse control disorders (ICDs) are a common
neuropsychiatric complication of Parkinson’s disease (PD).
By definition, ICDs refer to pathological behaviors characterized
by failure to resist an impulse, drive or temptation to perform an
act that is harmful. Usually, the affected individual experiences
pleasure, gratification, or relief at the time of committing
the act (1). Common ICDs in PD include dysfunctional
behaviors related to gambling, sex, food intake, shopping,
and hobbies. In the context of PD, these and other ICD-
related behaviors are increasingly regarded as behavioral
addictions (2–4).
ICDs are uncommon in the general population and in
untreated PD patients (5–7). Among PD treatments, dopamine
agonists (DAA) are strongly associated with ICDs (5). Patients
receiving DAA for a disorder other than PD also have a high risk
of ICDs (8, 9). However, other risk factors are important for their
development and phenomenology as most patients taking DAA
will not develop ICDs, and the best clinical-genetic predictive
models for the development of ICD symptoms explains only part
of the risk (4).
Not only ICD frequency is worrisome, but also for their
range of severity. Severity may vary from extremely disruptive
addictions causing bankruptcy, divorce, or even criminal
prosecution (10, 11) to mild addictive symptoms—usually
related to increased creativity or productivity—that may be
even perceived as positive for patients’ functionality (12, 13).
It is also worth noting that 13–39% of patients with ICDs do
not experience improvement or remission of the addictions
after dopamine agonists withdrawal (3, 14–16). It is therefore
important not only to study risk factors for the development
of ICDs, but to identify the variables responsible for different
prognosis and severity.
Impulsivity is a psychological construct characterized by poor
control of thoughts and actions with a propensity to react
fast over urges and environmental demands despite potential
negative consequences. The definition of impulsivity shares
obvious aspects with that of ICDs, and impulsivity is usually
considered to have a causal relation with ICDs in PD. Higher
scores on the Barratt Impulsiveness Scale (BIS-11), a self-
reported questionnaire with semi-quantitative responses, have
been observed in PD patients with and without ICDs (17, 18).
Other modes of impulsivity, such as deficit of motor inhibition,
have also been studied (18). Yet, studies on the influence of
impulsivity for the development and clinical manifestations of
ICDs in PD are scarce (17, 19).
In the present study, we aimed to explore the relation
between impulsivity and frequency and severity of ICDs
in PD. We assessed impulsivity and ICDs in PD patients
who were taking dopaminergic drugs. Only incident cases
of ICDs were included to avoid confounding factors such
as changes in dopaminergic medication and a bias toward
chronic ICDs. If impulsivity was a true risk factor for ICDs
in PD we would expect higher levels of impulsivity in patients
with ICDs.
MATERIALS AND METHODS
Consecutive PD outpatients followed at theMovement Disorders
Unit at Hospital de la Santa Creu i Sant Pau were invited
to participate. Inclusion criteria were idiopathic PD, active
treatment with a dopaminergic agent and last follow up at
the same center including ICDs evaluation within the last
6 months. Exclusion criteria were: any other neurological
condition, history of brain surgery, dementia according to
Movement Disorder Society PD-dementia criteria (20), inability
to perform the proposed tasks, use of dopamine antagonists,
unstable medical or psychiatric conditions (depression and
anxiety under effective and stable treatment were not excluded),
and presence of ICD in the previous follow up. Excluding
patients with previous ICDs was chosen to get measures
of the exposures as close to ICD inception as possible
and to avoid bias generated by medication changes and
chronicity.
Patients were informed about the study during follow-up
visits. If they agreed to participate in the study, they returned
for the study evaluation. Patients were not excluded if ICDs
were suspected or diagnosed the day they were informed about
the study. In such cases, no changes in medication were made
before the study protocol was completed (always within a week).
All the participants were evaluated by a neurologist trained in
movement disorders and a neuropsychologist experienced in
PD. All the patients gave written informed consent and the
study protocol was approved by the clinical research ethics
committee at Hospital de la Santa Creu i Sant Pau. All the
study was conducted according to the principles expressed in the
Declaration of Helsinki. All the evaluations were performed on
medication.
ICDs Diagnosis and Rating
The presence of ICDs was assessed through a comprehensive
clinical interview. ICDs were considered present when the related
behavior was dysfunctional according to the components of
addiction proposed by Brown (21) andmodified by Griffiths (22).
This model considers six components that comprise addiction
regardless of the involvement of drug use: salience, mood
modification, tolerance, withdrawal symptoms, conflict, and
relapse. At least 4 of the 6 components needed to be present to
consider a behavior as ICD. To diagnose a patient with more
than one ICD, each ICD had to be unrelated to the others and
considered dysfunctional.
To obtain a semiquantitative measure of severity in patients
with a diagnosis of ICD, we used the short version of the
questionnaire for impulsive-compulsive disorders in PD (QUIPs)
(23) (score range 0–13), the Minnesota Impulsive Disorders
Interview (MIDI) (24) (score range 0–56), and the number of
different ICDs. The number of ICDs was based on the clinical
interview. ICD diagnosis and QUIPs score were considered main
outcomes and the other ICD related variables were considered
exploratory. The investigator rating the main outcomes was
blinded to impulsivity measures.
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Impulsivity Evaluation
Impulsivity was evaluated using two different approaches, the
BIS-11 and the PEBL Continuous Performance Test (PCPT).
The BIS-11 was designed to assess the personality trait of
impulsiveness (25). It has 30 self-reported items grouped in
three subtraits: motor, attentional, and nonplanning. We used
BIS-11 as a subjective estimator for impulsivity. The PCPT is
a continuous performance task programmed in the Psychology
Experiment Building Language (26) based on the Conners
Continuous Performance Task II (27). The PCPT was designed
to assess motor inhibition and sustained attention. Participants
have to press a key in response to any capital letter (except X)
that appears on the screen. At the same time, they must refrain
from responding to lures (any X that appears). Targets are much
more common than lures, creating a tendency to respond to lures,
an inhibition failure. Commission error rate (CE)—failure to
avoid responding to lures—was used as an indirect but objective
measure of impulsivity (28). The investigator rating impulsivity
measures was blinded to patient outcomes (presence and severity
of ICDs).
PD-Related Variables
We recorded the motor part of Unified Parkinson’s Disease
Rating Scale (UPDRS-III) (29), Hoehn and Yahr stage (H&Y),
age at PD onset, PD duration, and current medical treatment.We
calculated the Levodopa equivalent daily dose (LEDD) and the
amount of LEDD corresponding to dopamine agonists (agonist-
LEDD) according to previously reported conversion factors (30).
We also recorded personal use of legal drugs (caffeine, nicotine
and alcohol), use of illegal drugs and both personal and family
history of alcohol and illegal drugs use disorders.
Data Analysis
Patients with and without ICD (ICD+/ ICD-) were compared.
The chi-squared test was used for discrete variables. When this
was inappropriate, the Fischer exact test was used. For most
quantitative variables we used mean and Student’s t-test and
for those which did not comply with parametric assumptions
we used median and Mann–Whitney U-test. We used Pearson
correlations in ICD+ patients to analyze the relationship between
ICD severity and other variables. Linear regression was used to
assess whether impulsivity independently explained ICD severity
and to control for motor state (UPDRS III) when comparing
medication doses between groups. Logistic regression was used
to assed which variables were independently associated with
ICD diagnosis. The level of significance was set as p < 0.05,
2-sided. Main objectives were the comparison of BIS-11 score
between ICD+ and ICD- and the correlation between BIS-
11 with severity among ICD+ (measured by QUIPs). Multiple
comparison adjustment was performed for these two tests by
Bonferroni (using the number of tests performed for impulsivity
and ICD diagnosis and for impulsivity and ICD severity).
The other statistical analysis were considered exploratory and
significance was not adjusted. Confidence intervals (CI) are
reported at 95% level. All the statistical analyses were conducted
using R version 3.1.3 (31).
RESULTS
ICD Frequency
One hundred consecutive PD patients (54 male, age mean ± SD
67 ± 9, education 11 ± 5, age at PD diagnosis 61 ± 9) were
recruited and ICDs were diagnosed in 31. Thirty-eight patients
had a positive score in QUIPs and 19 in MIDI.
The behaviors causing ICDs were hobbism/punding (n= 15),
binge-eating (n = 14), pathological hypersexuality (n = 5), and
compulsive shopping (n = 5). Hobbism/punding behaviors were
tidying (n = 6), board games (n = 3), social networking (n = 3),
repairing (n = 2), computer assisted edition (n = 2), and one
case each of compulsive reading, doll handcraft, dancing, and
walk-about. Eleven patients had several unrelated ICDs. None
had pathological gambling or dopamine dysregulation syndrome.
ICD+ patients were 5.25 years younger at the time of the
study (CI 1.24–9.25, p = 0.01) and at PD onset (p = 0.017).
They were also more frequently receiving treatment with a DAA
(59.4 vs. 83.9%, CI 4.7–44.1%, p = 0.02). No differences were
found regarding time since PD diagnosis, Hoehn & Yahr stage,
or UPDRS III status (Table 1).
Most patients in the sample were taking DAA: 41 used
pramipexole, 11 ropinirole, and 15 rotigotine (among ICD+
patients 16, 4 and 6, respectively). No patients used more than
one DAA. Average agonist-LEDD was higher in ICD+ patients
(p = 0.012) but this difference was due to the higher proportion
of DAA use in the ICD+ group (59.4% among ICD-, 83.9%
among ICD+; chi-square test p = 0.02). Among patients taking
DAA, no differences were found in agonist-LEDDbetween ICD+
and ICD- groups (p = 0.17). No difference was found after
adjusting for UPDRS III (p= 0.22). Levodopa dose was similar in
both groups (p = 0.35) and remained similar after adjusting for
UPDRS III (p= 0.07).MAO-B inhibitors and amantadine use did
not differ between groups (p = 0.96 and p = 0.22, respectively).
LEDD showed a trend toward significance, with higher doses
in ICD+ patients (p = 0.08). However, after controlling for
UPDRS III this difference became clearly significant (p = 0.008),
indicating that for a comparable degree of motor severity, ICD+
patients were taking higher LEDD.
No differences between ICD- and ICD+ groups were found
either in BIS-11 (56.35 vs. 58.33, unadjusted p = 0.23, adjusted
p = 0.46,) or in CE (p = 0.96) (Table 1). Neither BIS-11 nor CE,
were related to LEDD, DAA use or agonist-LEDD (Table 2).
None of the patients had begun to consume legal or illegal
drugs after PD diagnosis. No association was found between the
current amount of alcohol intake and ICDs (p =0.46). However,
current alcohol use was associated to ICD (41.5 vs. 12.9%,
OR = 5.42, CI = 1.64 - 23.61, p = 0.003), and patients with no
history of alcohol use had a significantly lower prevalence of ICDs
(6.7 vs. 34.5%, OR= 0.13, CI = 0.01-0.95, p= 0.03). Most of the
participants did not remember the age of first alcohol use and
therefore it was not analyzed.
Current tobacco use was associated with ICDs (OR = 5.17,
CI = 1.05–34.44, p = 0.02), although <10% of our sample
were current smokers and the average tobacco consumption
did not differ between groups (p = 0.25). Lifetime tobacco
consumption was more common (52%) but its association with
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TABLE 1 | Clinical and behavioral description of the sample.
ICD- (n = 69) ICD+ (n = 31) p-value
Age, years 68.79 ± 7.82 63.55 ± 9.77 0.01
Gender, male (%) 37 (53.6) 17 (54.8) 0.91
Age at PD onset, years 62.5 ± 7.75 57.5 ± 9.52 0.02
Evolution, months 65.6 ± 3.76 77.8 ± 3.87 0.25
UPDRS III 23.4 ± 9.88 19.9 ± 9.65 0.11
H&Y* 2(2-2.5) 2(2-2) 0.06
LEDD, mg 533.1 ± 451.6 702.2 ± 416.9 0.07
Proportion of agonist use
(%)
41 (59) 26 (84) 0.02
QUIPs 0.06 1.84 <0.001
MIDI 0.29 3.3 <0.001
BIS-11 56.35 ± 7.0 58.33 ± 7.72 0.23
Motor 19.31 ± 2.52 19.37 ± 2.95 0.93
Nonplanning 20.79 ± 4.07 22.23 ± 4.7 0.15
Attentional 16.25 ± 1.98 16.73 ± 1.98 0.27
PCPT commission errors
ratio
0.378 ± 0.2 0.376 ± 0.2 0.96
PCPT correct RT, ms 480 ± 75 465 ± 57 0.24
PCPT error RT, ms 447 ± 163 426 ± 131 0.49
PCPT correct targets ratio 0.94 0.95 0.59
Current smokers (%) 3 (4.3) 6 (19) 0.02**
Lifetime smokers (%) 32 (46) 20 (65) 0.93
Age at smoking onset 19.65 ± 4.48 15.53 ± 3.11 <0.001
Current alcohol users (%) 41 (59) 27 (87) 0.006
Lifetime alcohol users (%) 52 (75) 30 (97) 0.009
Lifetime illegal drugs
users (%)
3 (5) 4 (14) 0.20**
Mean ± standard deviation and proportions are shown unless otherwise specified. t-
test is used for central measures and Chi-square for proportions unless other test
specified. * Median (interquartile range), Wilcoxon–Mann–Whitney test significance is
shown. **Fisher exact test significance is shown.
ICD, impulse control disorder; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s
Disease Rating Scale; H&Y Hoehn and Yahr scale; LEDD, levodopa equivalent daily
dose; QUIPs, Short version of Questionnaire for Impulsive-Compulsive Disorders, MIDI,
Minnesota Impulsive Disorders Interview; BIS-11, Barrat Impulsiveness Scale; PCPT,
PEBL Continuous Performance Task; RT, reaction time; ms, milliseconds.
TABLE 2 | Correlation matrix of impulsivity and dopaminergic medication.
BIS-11 CE LEDD Agonist-LEDD
BIS-11 r = 0.03 r = 0.03 r = 0.03
CE p = 0.76 r = 0.1 r = −0.12
LEDD p = 0.77 p = 0.33 r = 0.43
Agonist-LEDD p = 0.78 p = 0.22 p < 0.001
BIS-11, Barrat Impulsiveness Scale; CE, Commission Error rate in PEBL Continuous
Performance Task; LEDD, Levodopa equivalent daily dose (mg/d), Agonist-LEDD,
Levodopa equivalent daily dose corresponding to dopamine agonists(mg/d).
ICDs was not statistically significant (OR = 2.09, CI = 0.81–
5.61, p = 0.09). However, patients who had begun smoking at
18 years old or younger were more likely to present ICDs than
older first time smokers (OR = 7.18, CI 1.29–76.3, p = 0.01)
and ICD+ patients had started smoking 4 years earlier on
TABLE 3 | Correlation matrix of impulsivity and ICD severity among ICD+.
BIS-11 CE QUIPs MIDI N. of ICDs
BIS-11 r = 0.03 r = 0.33 r = 0.30 r = 0.30
CE p = 0.75 r = 0.53 r = 0.38 r = 0.53
QUIPs p = 0.001 p = 0.006 r = 0.68 r = 0.9
MIDI p = 0.002 p = 0.04 p < 0.001 r = 0.70
N. of ICDs p = 0.003 p = 0.006 p < 0.001 p < 0.001
ICD, impulsive control disorders; BIS-11, Barrat Impulsiveness Scale; CE, Commission
Error rate in PEBL Continuous Performance Task; QUIPs, Short version of Questionnaire
for Impulsive-Compulsive Disorders; MIDI, the Minnesota Impulsive Disorders Interview;
N. of ICDs, number of ICDs.
average (15.5 vs. 19.7 y.o., p < 0.001). Current and previous
coffee intake was not related to ICDs (p = 0.73 and p = 0.67,
respectively).
No patient was currently using illegal drugs and previous
use was not significantly related to ICD diagnosis (OR = 3.26,
CI = 0.51–23.87, p = 0.19). No association was found between
ICDs and family history of drug or alcohol abuse (OR = 2.48,
CI = 0.76–8.02, p = 0.08). Only one of the 18 patients who had
never consumed alcohol on a regular basis and were not current
smokers had ICDs (Fischer exact test p= 0.01).
Multiple logistic regression showed that only current alcohol
consumption and age were independently associated with ICD
diagnosis (Supplementary material).
ICD Severity
Among ICD+ we studied correlations patients between
impulsivity measures and ICD severity measures. BIS-11 and
QUIPs correlated significantly (r = 0.33, unadjusted p = 0.001,
adjusted p = 0.002). We also found positive, significant
correlations between each impulsivity measure and each severity
measure, a correlation matrix is shown in Table 3. However, no
correlation was found between BIS-11 and PCPT commission
error rate (Pearson’s r = 0.03, p = 0.75). Other variables related
to ICD frequency were not statistically associated to severity
measures (Supplementary Material).
We performed multiple linear regression analysis to study
whether each impulsivity estimator independently explained
QUIPs in ICD+ patients. As the other tested variables were not
statistically associated with QUIPs, we included as independent
variables the ones that were associated with ICD presence except
for age of smoking onset (because 32% of the ICD+ patients
had never smoked) and history of alcohol use (because only one
ICD+ patient had never used it). QUIPs score was the predicted
value. We also used bidirectional stepwise regression to select the
predictors. Both impulsivity measures—BIS-11 and commission
error rate—significantly predicted QUIPs in the “all in” model.
Current smoking was also a significant predictor. These were also
the only variables selected by bidirectional stepwise regression
(Table 4).
DISCUSSION
The present results show a complex interaction between DAA
and impulsivity with the presence and severity of ICDs in
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TABLE 4 | Multiple linear regression models using QUIPs as the dependent
variable among ICD+.
Adjusted R2 Estimate t p
All-in model 0.5974
(Intercept) −3.55 −1.82 0.08
LEDD 0.00006 0.13 0.90
DAA use 0.055 0.11 0.91
Age 0.0007 0.037 0.97
BIS-11 0.065 2.45 0.02
CE 4.57 4.56 <0.001
Current alcohol user −0.459 −0.86 0.40
Current smoker 1.26 2.39 0.03
Stepwise, both directions
model
0.6452
(Intercept) −3.52 −2.63 0.01
BIS-11 0.06 2.58 0.02
CE 4.35 4.82 <0.001
Current Smoker 1.24 2.57 0.02
QUIPs, Short version of Questionnaire for Impulsive-Compulsive Disorders; ICD, impulsive
control disorders; LEDD, levodopa equivalent daily dose; DAA, dopamine agonists;
BIS-11, Barrat Impulsiveness Scale; CE, Commission Errors.
PD patients. Contrary to our hypothesis impulsivity was not
significantly higher in patients with ICD. However it was
associated with higher severity of ICDs. This suggests that the
role of impulsivity in ICD presence may be weak or nonexistent
but it has an important role regulating ICD severity. The use
of DAA, as previously shown, is associated with the presence of
ICDs, but not with impulsivity or with ICD severity. Therefore
DAA seem to have a critical role in ICD inception but not in their
severity.
The fact that LEDDwas higher in ICD+ only after controlling
for motor severity might indicate that ICDs are related to an
imbalance of dopaminergic activity between dorsal and ventral
striatum. Higher doses of dopaminergic medication to control
motor symptoms could promote overdosing of the ventral
striatum (32), but our study is not designed to address this
hypothesis.
Other studies have found higher levels of impulsivity in
ICD+ patients (17). This discrepancy with our findings may
be due to different study designs. Case-control studies select
previously diagnosed patients who are more likely to have more
severe ICDs (33). Systematic screening of consecutive patients
permits to identify less conspicuous but relevant cases. Therefore,
our sample, which excluded patients with previously known
ICDs, is more likely to be enriched with less severe addictive
behaviors. Both approaches are valid and useful to serve different
purposes. The selection bias in case-control studies increases the
probability to rule out suspected differences because the expected
difference between groups is higher. Cross sectional studies
such as the present study tend to produce more representative
results. Another plausible explanation for the lack of significant
differences in impulsivity between ICD+ and ICD- patients is
based on the type of ICDs found in our sample. None of our
patients had pathological gambling, while other studies analyzing
risk factors for ICDs in PD included almost exclusively patients
with gambling, a condition known to be highly related to elevated
impulsivity (34).
The double dissociation exhibited by impulsivity and
dopamine agonist use suggests that dopamine agonist do not
cause PD-ICDs by means of fostering impulsivity. Impulsivity
promotes the expression of the disorder not restraining the
behaviors that constitute it. Conversely, the existence of an
impulse able to constitute a disorder, would be caused by the
imbalance generated by dopaminergic medication in the reward
system (35). Accordingly, impulsive behaviors not generally
linked to reward, such as reckless driving or domestic violence
are quite rare in PD patients. Nonetheless, a minimum grade
of impulsivity may be required as a perfect self-control would
preclude any addictive behavior.
As previously reported (5), we found the use of legal drugs
are greatly associated to ICDs. Drug use is linked to both
reward imbalance and impulsivity, not shedding light on the
discussed dissociation. In this sample, alcohol consumption was
associated with the presence while tobacco was associated with
both presence and severity of ICDs. The use of both drugs
precedes ICDs development in this study, therefore they act as
risk factors. History of alcohol and tobacco use is easily available
information and probably not usually taken into account prior
to DAA prescription as it has not been used in predictive
models (4).
Our study has several limitations and strengths. The first
limitation is that QUIP short has not been properly validated as
a measure of ICD severity. However, it is considered sensitive,
reliable, easy to answer accurately and able to capture ICD
severity (23). A rating scale has been validated for ICD severity,
the QUIP rating scale (36). This scale is closely related to
QUIP short. To overcome this limitation, MIDI and the number
of ICDs have also been studied yielding similar statistical
correlations. Second, the design does not probe that impulsivity
antecedes ICDs. Prospective studies are necessary to confirm
causality. The strengths of our study are: (1) the assessment
of two unrelated modes of impulsivity, showing that they were
independently related to ICD severity; (2) the use of behavioral
addiction criteria to diagnose ICDs, allowing the use of the same
criteria independently of the studied behavior; and (3) a sample
of systematically interviewed consecutive outpatients, avoiding
selection bias.
CONCLUSIONS
In summary, we found impulsivity is more associated with
severity of ICDs than with ICD diagnosis. Conversely, we
found DAA are associated the diagnosis of ICDs but are not
associated with their severity. We also show how previous
and current use of legal drugs is strongly related to the
appearance and severity of ICDs. Further research is needed
to evaluate whether impulsivity and legal drug use should
be taken into account before prescribing DAA, and whether
treatment strategies focused on decreasing impulsivity (37)
in PD patients with ICDs would help to control these
behaviors.
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